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Different Prognostic Significance of
High On-Treatment Platelet Reactivity as
Assessed by the VerifyNow P2Y12 Assay After
Coronary Stenting in Patients With and Without
Acute Myocardial Infarction
Sung Gyun Ahn, MD,* Seung-Hwan Lee, MD, PHD,* Jin-Ha Yoon, MD,†
Woo Taek Kim, MD,* Jun-Won Lee, MD,* Young-Jin Youn, MD,* Min-Soo Ahn, MD,*
Jang-Young Kim, MD, PHD,* Byung-Su Yoo, MD, PHD,* Junghan Yoon, MD, PHD,*
yung-Hoon Choe, MD, PHD*
Wonju, South Korea
Objectives This study compared the prognostic role of high on-treatment platelet reactivity (HTPR)
in predicting thrombotic events in a Korean population undergoing percutaneous coronary interven-
tion (PCI) in the acute myocardial infarction (AMI) and non-AMI setting.
Background The prognostic signiﬁcance and optimal cutoff of HTPR might differ according to a
given clinical condition, such as AMI and ethnicity.
Methods On-treatment platelet reactivity was measured with a VerifyNow P2Y12 assay (Accumet-
rics, San Diego, California) in 1,226 patients (824 men; age 65  10 years), including 413 AMI cases,
12 to 24 h after PCI between March 2008 and March 2010. The prevalence of cardiovascular (CV)
events deﬁned as a composite of death from CV causes, nonfatal myocardial infarction, or stent
thrombosis at 1-year follow-up were compared according to HTPR between patients with and
without AMI.
Results The optimal cutoff for HTPR was 272 IU of the P2Y12 reaction unit (PRU) (area under the
urve: 0.708; 95% conﬁdence interval [CI]: 0.607 to 0.809, p  0.03), which was the upper-tertile
hreshold. Among AMI patients, 1-year CV events occurred more frequently in patients with versus
ithout HTPR (n  14 [8.8%] vs. n  1 [0.4%], p  0.001), whereas there was no difference in the
composite endpoint on the basis of HTPR in patients without AMI (n  7 [2.8%] vs. n  8 [1.4%],
p  0.193).
Conclusions Increased residual platelet reactivity is related to post-discharge CV events in subjects
with AMI, whereas the prognostic signiﬁcance of HTPR seems to be attenuated in patients with sta-
ble coronary disease after PCI. (J Am Coll Cardiol Intv 2012;5:259–67) © 2012 by the American
College of Cardiology Foundation
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260The response to clopidogrel varies considerably, due to several
mechanisms, including absorption and hepatic conversion to its
active metabolite (1). High on-treatment platelet reactivity
(HTPR) to adenosine diphosphate has been found to be a
predictor of major adverse cardiovascular (CV) events, such as
death from CV causes, nonfatal myocardial infarction (MI), and
stent thrombosis in patients with coronary artery disease (CAD)
after percutaneous coronary intervention (PCI) (2–5). The
numerous studies (2,5–7) with the VerifyNow P2Y12 assay
(Accumetrics, San Diego, California) showed a concrete
association between HTPR and thrombotic events. The
optimal cutoff values for HTPR ranged between 230 and
240 IU of the P2Y12 reaction unit (PRU) among studies,
hich were approximately upper-tertile values (2,5–7). An
xpert group suggested a similar cutoff value for HTPR (8).
See page 278
We hypothesized that the prognos-
tic role and cutoff of HTPR might
differ according to a given clinical
condition, such as acute myocar-
dial infarction (AMI), ethnicity,
and sampling time. Therefore, we
aimed to evaluate whether the prog-
nostic role of HTPR as assessed
with the VerifyNow P2Y12 assay
differs between AMI and non-
AMI settings. We also sought to
investigate the optimal cutoff for
HTPR in predicting CV events in
Korean subjects undergoing PCI.
Methods
The study protocol was ap-
proved by the Ethical Review
Board of Wonju College of Medicine, Yonsei University
(Wonju, South Korea). Informed consent was obtained
from all participants.
Study population. Clinical, laboratory, and angiographic
ata were collected consecutively and prospectively in 1,650
ubjects who underwent PCI with drug-eluting stents at
onju Christian Hospital between March 2008 and March
010. One hundred forty-seven patients did not consent to
articipate in the study. Eighteen patients died during the
rocedure or the hospital stay before the VerifyNow P2Y12
ssay was carried out. Eighty-three patients concomitantly
eceived glycoprotein IIb/IIIa inhibitors. One hundred
hirty-one patients did not have platelet function tests.
ther exclusion criteria were contraindications for anti-
latelet therapy, previous use of anticoagulants, severe left
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CI  confidence interval
CV  cardiovascular
DM  diabetes mellitus
HR  hazard ratio
HTPR  high on-treatment
platelet reactivity
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction unit
ROC  receiver-operating
characteristicentricular dysfunction (ejection fraction 30%), cardio-enic shock, neoplastic disease, platelet count150,000/ml,
nd hemoglobin 10 g/l. Thus, the total study cohort
omprised 1,226 subjects, including 413 patients with AMI
186 non–ST-segment elevation MI and 227 ST-segment
levation MI) (Fig. 1).
Coronary angiography and antithrombotic regimens. All
patients received aspirin (300 mg) and clopidogrel (600 mg)
before the start of the coronary procedure. A bolus of
unfractionated heparin (70 U/kg) was administered imme-
diately before PCI. The PCI was undertaken via a transra-
dial or transfemoral approach with conventional methods
with balloon pre-dilation followed by drug-eluting stent
deployment. In AMI cases, aspiration thrombectomy was
used at the discretion of the operator. Aspirin (100 mg) and
clopidogrel (75 mg) were given for 12 months after PCI.
iving cilostazol in addition to dual antiplatelet therapy was
ermitted, depending on the preference of the clinician only
fter the platelet function assay.
Blood sampling and the VerifyNow P2Y12 assay. Blood
samples were obtained 12 to 24 h after PCI. Irrespective of
prior exposure to clopidogrel, 600 mg was administered
before PCI. Each sample was placed in a tub containing
3.2% citrate, and the PRU was assessed within 2 h with the
VerifyNow P2Y12 test as previously described (9). The
HTPR was defined as 272 PRU. This cutoff was chosen
because it was: 1) the upper-tertile value in the study cohort;
and 2) similar to those used in the receiver-operating
characteristic (ROC) curve analysis to identify HTPR for
the prediction of CV events in Korean patients with CAD
(10–13).
Main outcome measures. The primary endpoint was the
1-year prevalence of the composite of death from CV
causes, nonfatal MI, or stent thrombosis. All deaths were
considered CV unless an unequivocal non-CV cause could
be confirmed. Myocardial infarction was defined according
to criteria set by the American College of Cardiology (14) as
a rise in serum troponin I or an increase in creatine
kinase-myocardial band isoenzyme at least twice the upper
normal limits with at least 1 of the following: acute onset of
prolonged (20 min) typical ischemic chest pain; ST-
segment elevation of at least 1 mm in 2 or more contiguous
electrocardiographic leads or ST-segment depression 0.5
mm in2 contiguous leads; or T-wave inversion1 mm in
leads with predominant R waves. Stent thrombosis was
defined as “definite” or “probable” according to definitions
set by the Academic Research Consortium (15).
Statistical analyses. Continuous variables are presented as
mean  SD or median (intertertile range), and categorical
variables are presented as frequencies (percentage). Contin-
uous variables were compared with the Student t test. The
chi-square test or Fisher exact test were used if the expected
cell count was 5 for a 2  2 table for categorical variables.
The ROC analyses were used to determine the ability of the
PRU to discriminate between patients with and without
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261post-discharge CV events after PCI. The upper-tertile PRU
value (272) was determined as the optimal cutoff for HTPR
that provided reasonably high sensitivity (70%) and high
specificity (68%). Survival curves for patients with and
without HTPR were generated by the Kaplan–Meier
method and compared with the log-rank test. The afore-
mentioned analyses were undertaken separately in patients
with and without AMI. After assessment of the propor-
tional hazard assumption, the Cox regression model for
univariate and multivariate analyses were used, respectively,
to identify risk factors for outcome and to adjust for
potential confounders associated with endpoints upon uni-
variate analysis (age, sex, diabetes mellitus [DM], chronic
kidney disease, C-reactive protein level 3 mg/l, AMI
setting, HTPR, reduced left ventricular ejection fraction,
multivessel disease, total length of stent and bifurcation
lesions). A p value 0.05 was considered significant. All
analyses were carried out with SPSS (version 17.0, SPSS,
Chicago, Illinois).
Results
Between March 2008 and March 2010, 1,226 patients were
screened with platelet function testing 12 to 24 h after PCI.
Of these, 410 patients had HTPR (Fig. 1). Baseline clinical,
lesion, and procedural characteristics according to HTPR
are summarized in Table 1. Patients with HTPR were older
Figure 1. Study Flow Chart
The diagram shows process of the present study. AMI  acute myocardial infa
ejection fraction; PCI  percutaneous coronary intervention.(67  11 years vs. 62  11 years, p  0.001) and less likely To be men (50.2% vs. 75.5%, p  0.001). The presence of
M or hypertension, being a current smoker, having previously
ndergone PCI or coronary artery bypass grafting, and renal
nsufficiency were not associated with HTPR. The preva-
ence of concurrent use of medications between the 2 groups
as quite similar, except for statins (which were taken less
requently by patients with HTPR). The number of vessels
reated/patient was higher (1.9  0.8 vs. 1.8  0.8, p 
.013) and the mean diameter of the stent was smaller in
atients with HTPR (3.20 0.47 mm vs. 3.28 0.48 mm,
 0.003). Higher mean on-treatment platelet reactivity
as observed in patients with versus those without AMI
241  94 PRU vs. 229  83 PRU, p  0.018).
Outcomes at 1 year in patients stratiﬁed by post-clopidogrel
platelet reactivity. Clinical follow-up at 1 year was complete
n 1,220 (99.5%) participants. After discharge, there were
0 patients with CV events (2.4%), including 18 CV deaths
1.5%), 16 nonfatal MI (1.3%), and 19 episodes of stent
hrombosis (1.6%). Patients with adverse events had signif-
cantly higher on-treatment platelet reactivity than those
ho did not experience events (290 84 PRU vs. 232 86
RU, p  0.002). Patients with HTPR had a significantly
reater prevalence of CV mortality (14 [3.4%] vs. 4 [0.5%],
 0.001) and stent thrombosis (13 [3.2%] vs. 6 [0.7%],
 0.001) and a combined endpoint of CV death, nonfatal
I, or stent thrombosis (21 [5.1%] vs. 9 [1.1%], p  0.001).
; HTPR  high on-treatment platelet reactivity; LVEF  left ventricularrctionhere was no difference concerning the prevalence of
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262nonfatal MI between the 2 groups (8 [1.0%] vs. 8 [2.0%],
p  0.158). Table 2 demonstrates the prevalence of events
etween patients with and without HPR as stratified by
MI status. Among patients without AMI, no difference in
he prevalence of events was found between the 2 groups,
hereas composite CV events occurred more frequently in
atients with HTPR than in those without HTPR in the
MI group (8.8% vs. 1.6%, p  0.002). Patients with AMI
and HTPR had a higher prevalence of CV death (6.9% vs.
0.7%, p  0.001) and stent thrombosis (4.4% vs. 0%, p 
0.001) than those without HTPR.
The event-free survival curves for the combined endpoint of
CV events according to the presence of HTPR are shown in
Table 1. Baseline Clinical and Procedural Characteri
Residual platelet reactivity, PRU
Age yrs
Men
Body mass index, kg/m2
Medical history
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker
Prior MI
PCI
CABG surgery
Renal insufﬁciency
Concomitant medication
Beta-blocker
Calcium-channel blocker
ACE inhibitor or ARB
Statin
Proton pump inhibitor
Cilostazol
Indication for procedure
Stable angina or unstable angina without
elevated cardiac enzymes
NSTEMI
STEMI
Left ventricular ejection fraction, %
Procedural variables
Vessels/patient
Stents/patient
Total stent length, mm
Stent diameter, mm
Left main lesion
Bifurcation lesion
Values are n (%) or mean SD.
ACE angiotensin-converting enzyme; ARB angiotensin recepto
platelet reactivity; MImyocardial infarction; NSTEMI non-ST-segm
tion; PRU P2Y12 reaction unit; STEMI ST-segment elevation myocFigure 2. One-year survival free from the combined endpointof CV death, nonfatal MI, or stent thrombosis was 94.9% in
patients with HTPR and 98.9% in patients without HTPR
(Fig. 2A) (p  0.001). Among patients without AMI, no
differences in event-free survival were found according to the
presence of HTPR (Fig. 2B) (p  0.196), whereas patients
with AMI and HTPR had a higher prevalence of events than
those without HTPR (Fig. 2C) (p  0.001).
Only 172 patients (14%) received cilostazol in the present
population. There was no significant difference in clinical
outcome according to use or no use of cilostazol (3.5% vs.
2.1%, p  0.256).
Platelet reactivity and ROC curve analyses. The PRU was
unimodally distributed (1-sample Kolmogorov–Smirnov
f Study Patients on the Basis of HTPR
TPR HTPR
816) (n  410) p Value
60 328 43 0.001
11 67 11 0.001
(75.5) 206 (50.2) 0.001
3.3 24.8 3.2 0.777
(32.7) 132 (32.2) 0.853
(60.3) 254 (62.08) 0.575
(32.5) 128 (31.0) 0.657
(31.5) 123 (30.0) 0.602
(4.3) 16 (4.0) 0.598
(9.9) 49 (12.0) 0.277
(0.4) 2 (0.5) 0.755
(3.8) 14 (3.4) 0.685
(76.0) 325 (79.3) 0.315
(19.5) 67 (16.3) 0.186
(65.8) 291 (71.0) 0.135
(75.0) 271 (66.1) 0.001
(5.3) 25 (6.1) 0.550
(12.9) 67 (16.3) 0.097
0.022
(68.9) 251 (63.5)
(14.3) 69 (16.1)
(16.8) 90 (20.4)
13 57 48 0.360
0.8 1.9 0.8 0.013
0.9 1.7 0.8 0.994
24 43 24 0.733
0.48 3.20 0.47 0.003
(3.4) 11 (2.7) 0.481
(15.3) 66 (16.1) 0.723
r; CABG coronary artery bypass surgery; HTPR high on-treatment
vation myocardial infarction; PCI percutaneous coronary interven-
farction.stics o
No H
(n 
185
62
618
24.9
267
493
265
257
35
81
3
31
620
159
537
612
43
105
562
117
137
55
1.8
1.7
42
3.28
28
125
r blocke
ent eletest, p  0.236) with mean value of 232  87 (intertertile
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263range 194 to 272). A ROC curve analysis of PRU could be
used to distinguish between patients with and without
subsequent CV events (area under the curve: 0.708, 95%
confidence interval [CI]: 0.607 to 0.809, p  0.001). If
divided between those with or without AMI, the area under
the curve was larger in patients with AMI (0.792, 95% CI:
0.708 to 0.876, p  0.001) compared with those without
MI (0.601, 95% CI: 0.433 to 0.769, p  0.180) (Fig. 3).
PRU 272 was identified as the optimal cutoff value to
redict post-discharge 1-year outcomes, providing a sensi-
ivity of 70% and specificity of 68%. In AMI patients,
TPR defined as PRU 272 had a sensitivity of 93% and
pecificity of 65%. Conversely, in non-AMI patients,
TPR could not be used to distinguish between patients
ith and without CV events.
Upon multivariate Cox regression analysis, HTPR was
ssociated with a significantly higher risk of CV death
hazard ratio [HR]: 7.352, 95% CI: 1.522 to 35.515, p 
.013) and the combined endpoint of CV events (HR:
.749, 95% CI: 1.400 to 10.04, p  0.009) after adjusting
or potential confounders that were associated with end-
oints on univariate Cox regression analysis (age, sex, DM,
hronic kidney disease, 3 mg/l of C-reactive protein,
45% of ejection fraction, AMI setting, multivessel disease,
otal stent length, and bifurcation lesions) There was a
onsignificant trend toward greater risk of stent thrombosis
n those with HTPR (HR: 2.833, 95% CI: 0.933 to 8.913,
 0.066). Low ejection fraction (45%), elevated creat-
inine level (1.5 mg/dl), and HTPR were independent
predictors for 1-year combined endpoint of CV events
(Table 3).
Discussion
The main finding of the present study was that HTPR
defined as 272 of PRU provided valuable prognostic
information in patients with AMI but that its prognostic
significance was attenuated in the non-AMI setting.
Numerous studies (2–5) have demonstrated an associa-
tion between increased residual platelet reactivity and sub-
Table 2. 1-Year CV Events According to Clopidogrel
No AMI (n  813)
No HTPR HTPR
(n  562) (n  251)
All CV events 8 (1.4) 7 (2.8)
CV death 3 (0.5) 3 (1.2)
Nonfatal MI 7 (1.2) 3 (1.2)
Stent thrombosis 6 (1.1) 6 (2.4)
Values are n (%).
CV cardiovascular; other abbreviations as in Table 1.sequent adverse outcome. Hence, individualized therapyaccording to HTPR has attracted the attention of many
researchers (16–18). Finally, the GRAVITAS (Gauging
Responsiveness with A VerifyNow assay–Impact on
Thrombosis And Safety) trial aimed to determine the
benefit of tailoring antiplatelet therapy with double-dose
clopidogrel in patients with HTPR but failed to demon-
strate improved outcome (7). Possible explanations of the
negative results are the relatively low-risk CAD patients
included; insufficiency of double-dose clopidogrel to over-
come HPR; and a lower prevalence of clinical events (2.3%
in both groups). That finding corresponds well with our
result of no differences in outcomes between patients with
and without HPR in the non-AMI setting. In line with this
observation, the TRIGGER-PCI (Testing Platelet Reac-
tivity in Patients Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy With Prasugrel)
trial, which assessed outcomes in patients with HTPR
undergoing elective PCI randomized to prasugrel or clopi-
dogrel, was recently halted due to the low prevalence of
events. The prognostic significance of HTPR on throm-
botic events might be attenuated in patients with stable
CAD after PCI because of the lower prevalence of events.
This negative finding of HTPR in non-AMI cohort might
be due to underpowering, because the proportion of all CV
events in HTPR group (2.8%) was still twice as high as
those in no HTPR group (1.4%). A large-size trial involving
approximately 1,723 subjects with stable coronary disease
would be required to achieve adequate power to show
whether HTPR is beneficial in predicting midterm post-
discharge CV risk (at p  0.05 both side, power  0.8).
Conversely, in the AMI subgroup, CV events occurred
more frequently in patients having HTPR. Thus, new strate-
gies (e.g., more potent antiplatelet agents or adding cilostazol
to standard dual-antiplatelet therapy) might be needed to
overcome HTPR in settings such as AMI, which enhances
platelet reactivity. Cilostazol had no impact on decreasing throm-
botic events in this study. Because only 14% of patients received
cilostazol and the present study was not designed to investigate the
clinical impact of cilostazol, further research is warranted to assess
nse, Stratified by AMI and HTPR
Value
AMI (n  413)
p Value
No HTPR HTPR
(n  254) (n  159)
.193 1 (1.6) 14 (8.8) 0.001
.383 1 (0.7) 11 (6.9) 0.001
.000 1 (0.7) 5 (3.1) 0.031
.158 0 (0) 7 (4.4) 0.001Respo
p
0
0
1
0clinical benefit of cilostazol in patients with HTPR.
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264Current methods to measure on-treatment platelet reac-
tivity have several innate shortcomings for thrombotic risk
stratification. First, they do not reflect total platelet reactiv-
ity; second, the soluble coagulation system in the plasma
also is pivotal in the development of thrombosis (19,20).
Third, much more than the effect of the antiplatelet agent is
being measured. Fourth, in studies of platelet reactivity in
individuals receiving no antiplatelet therapy, high reactivity
Figure 2. Survival Free From CV Death, Nonfatal MI, and Stent Thrombosis
(A) 1-year survival free from the combined endpoint of cardiovascular (CV) de
HTPR and 98.9% in patients without HTPR in the overall population. (B) Amon
to the presence of HTPR. (C) Patients with AMI and HTPR had a higher prevale
ations as in Figure 1.has also correlated with worse outcomes (21,22). Therefore,a greater emphasis on platelet reactivity being a risk marker
more than a guide for changing antiplatelet therapy would
help better balance the clinical applicability of the results.
Studies using the VerifyNow P2Y12 assay have suggested
that the optimal cutoffs of the PRU for low responsiveness
to clopidogrel were between 230 and 240 (2,5–7). These
cutoffs were based on the ROC analysis and corresponded
well with the upper-tertile values. Conversely, the cutoff of
nfatal myocardial infarction, or stent thrombosis was 94.9% in patients with
ents without AMI, no differences in event-free survival were found, according
f events than those without HTPR. PRU  P2Y12 reaction unit; other abbrevi-ath, no
g pati
nce othe PRU for HTPR in the present study (272) was quite
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265high. Recent studies in Korean populations have also
suggested a higher optimal cutoff for HTPR (10–12).
Although we did not directly compare the responsiveness to
clopidogrel between Korean populations and Caucasian
populations, the higher cutoff for HTPR suggests that the
response to clopidogrel decreased in Korean patients after
PCI. Price et al. (23) reported that non-Caucasians had a
higher PRU than Caucasians (229 vs. 200, p  0.041),
which is consistent with our results. This gap could be
partially explained by inter-racial variability, a higher pro-
portion of AMI in the study population (37.8%), and the
timing of measurements after PCI. Inter-individual vari-
ability in the responsiveness to clopidogrel is well known
(1), but data on inter-racial variability are unavailable.
Recent genetic research on the polymorphism of cyto-
chrome P450 (which is involved in the metabolism of the
pro-drug clopidogrel into its active component) could pro-
vide a clue on inter-racial variability. Patients with CYP2C19
loss of function alleles, which include CYP2C19*2 and
CYP2C19*3, have a higher PRU and worse outcome than
non-carriers (24–26). The prevalence of CYP2C19 loss of
unction varies considerably, depending on ethnicity. The
requency of the reduced-function variants of CYP2C19 was
Figure 3. ROC Curve for the VerifyNow P2Y12 Assay
A receiver-operating characteristic (ROC) curve analysis of the P2Y12 reac-
tion unit could be used to distinguish between patients with and without
post-discharge cardiovascular events (area under the curve: 0.708, 95%
conﬁdence interval [CI]: 0.607 to 0.809, p  0.001). If divided between
those with or without acute myocardial infarction (AMI), the area under the
curve was larger in patients with AMI (0.792, 95% CI: 0.708 to 0.876, p 
0.001) compared with those without AMI (0.601, 95% CI: 0.433 to 0.769,
p  0.180).uch higher in the Asian population than in Caucasians24,27). AMI is associated with heightened platelet reactiv-
ty. The higher proportion of AMI cases included is another
ossible explanation for the high HTPR cutoff in the
resent study. Price et al. (2) suggested an optimal cutoff of
he PRU 235 in patients with approximately 93% stable
ngina or ischemia, and the GRAVITAS trial (which
ncluded only approximately 10.5% of AMI cases) suggested
n optimal cutoff for HTPR 230 (7). The cutoff for
TPR in the present study was even higher, compared with
hat of a study comprising patients with acute coronary
yndrome, including 28% of cases of ST-segment elevation
I (6).
There is no consensus with regard to the appropriate
iming for the VerifyNow P2Y12 test. However, in most
tudies, the PRU was analyzed at 12 h after loading with
00 mg clopidogrel immediately before PCI or after PCI.
he PCI itself could activate platelet reactivity, leading to a
igher PRU value. Therefore, our higher PRU values might
ave been influenced by PCI itself, because we carried out
he VerifyNow P2Y12 test 12 to 24 h after PCI. We did this
ecause, in everyday practice, ad hoc PCI is done immedi-
tely after diagnostic coronary angiography in many patients
nd there are many emergency or urgent PCI cases. There-
ore, there is not enough time to reach steady concentration
f clopidogrel before PCI. Our PRU cutoff for HTPR
eems to represent platelet reactivity integrating PCI and a
iven setting, such as AMI. Matetzky et al. (4) showed that
ost-clopidogrel platelet reactivity might change dynami-
ally during the early phase of AMI and that it might
tabilize from Day 3 to Day 5 after coronary stenting in
MI patients. This finding suggests that the appropriate
ampling time for measurement of HTPR might be 3 to 5
ays later in the AMI setting. A recent study by Campo et
l. (28) claimed that the PRU measured 1 month after PCI
ight better predict post-discharge outcome. Thus, the
ptimal cutoff for HTPR should be determined after con-
idering the chronology of the sample time with respect to
CI in different clinical conditions.
Study limitations. First, this is a single-center study in a
orean population. Second, genetic studies were lacking, so
hypothesis about the higher cutoff for HTPR could not be
lucidated. Third, use of the VerifyNow P2Y12 assay might
Table 3. Predictors of Cardiovascular Events on
Multivariate Cox Proportional Hazard Analysis
Hazard Ratio Confidence Interval p Value
Female 2.692 0.984–7.187 0.054
AMI 2.397 0.996–5.688 0.051
EF 45% 2.679 1.057–6.792 0.038
Cr 1.5 mg/dl 4.719 1.285–17.327 0.019
HTPR 272 PRU 3.749 1.400–10.04 0.009
AMI  acute myocardial infarction; Cr  creatinine; EF  ejection fraction; HTPR  high on-treatment platelet reactivity; PRU P2Y12 reaction unit.
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266be associated with exclusion of higher-risk patients who
received a glycoprotein IIb/IIIa inhibitor. Other tests, such
as the vasodilator-stimulated phosphoprotein index might
have been more adequate, because this test is not influenced
by a glycoprotein IIb/IIIa inhibitor. However, the Verify-
Now P2Y12 assay is a point-of-care and easier test than the
vasodilator-stimulated phosphoprotein phosphorylation as-
say to assess HTPR. Fourth, a sizable proportion of approx-
imately 40% of all AMI patients was considered to have
high platelet reactivity, which diminishes the usefulness of
HTPR as a long-term predictive test. Fifth, we did a single
measurement of the PRU by the VerifyNow P2Y12 assay.
In addition to interindividual variability, there is consider-
able intraindividual variability, and clopidogrel responsive-
ness seems to improve over time (3,28,29). Enhanced
residual platelet reactivity does not seem to be a stable
phenomenon, and a 1-month PRU might better predict
adverse outcome (28). Repeat measurements might detect an
increase or decrease in clopidogrel responsiveness (30) and im-
prove the ability to distinguish patients with and without adverse
clinical events.
Conclusions
Increased residual platelet reactivity was related to post-
discharge CV events in subjects with AMI, whereas HTPR
did not seem to predict outcome in patients with stable
coronary diseases. The optimal cutoff of the PRU for
HTPR in our Korean study cohort was higher than that of
Caucasians. The different cutoff of the PRU for HTPR should
be used according to a given clinical setting, ethnicity, and
sampling time.
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